openPR Logo
Press release

Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2022

11-21-2017 01:23 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Research Beam Market

Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow

Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects, the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer.

For More Info, Get Sample: http://bit.ly/2zVmL28

The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015 and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common among all the types in addition to existing number of cancer patients.

The global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022.

Based on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large CINV patient pool and huge demand for the Netupitant–Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.

Enquire About Report : http://bit.ly/2zUh0RX

KEY BENEFITS

• The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.
• The study provides analysis of key market dynamics, which influence the adoption of CINV drugs
• The report provides a quantitative analysis for the period of 2014–2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.
• Extensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies.
• Competitive intelligence of market players highlights the business practices and trends across various regions.

KEY MARKET SEGMENTS:

Patient Pool Type

• Aloxi, Kytril
• Emend
• Netupitant-Palonosetron
• Others

Also Request For Discount : http://bit.ly/2AiuwzX

By Geography

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Rest of Europe
• Asia-Pacific
• China
• Japan
• Rest of Asia-Pacific
• LAMEA
• Latin America
• Middle East
• Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• GlaxoSmithKline plc
• Helsinn Holding S.A.
• Heron Therapeutics, Inc.
• Merck & Co., Inc.
• Tesaro, Inc

Table Of Content

• Chapter: 1 INTRODUCTION.
• Chapter: 2 EXECUTIVE SUMMARY
• Chapter: 3 MARKET OVERVIEW
• Chapter: 4 CINV MARKET BY PATIENT POOL
• Chapter: 5 CINV MARKET BY GEOGRAPHY
• Chapter: 6 COMPANY PROFILES

About Us
We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell are authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. Research Beam will always make sure to bring most ethical and high-quality reports. We value your relationship with us and look forward to a long-term relation.

Contact Us
Global Head Quarters
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
+1 (800) 910-6452
help@researchbeam.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2022 here

News-ID: 826584 • Views: 149

More Releases from Research Beam Market

Blood Plasma Derivatives Market Growing With $44,333 Million At A CAGR of 9.3% F …
Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor
Holter ECG Monitoring Market Growing $418.3 Million By 2023
Holter monitors are devices that allow prolonged monitoring of heart rhythm from a few days to several months, enabling the detection of infrequent arrhythmias in patients. In addition, holter monitors help identify ventricular tachycardia (VT) in patients with recognized risk of sudden cardiac death. Portability of holter monitors significantly propel the market growth as they can be easily worn by the patients to record heart activity for a certain period
Intermittent Catheters Market Reach $2,950.7 Million By 2023
The global intermittent catheters market was valued at $1,655.5 million in 2016, and is expected to reach $2,950.7 million by 2023 with a CAGR of 8.7% during the forecast period. Intermittent catheter is a disposable medical device, which is used to drain the urinary bladder when an individual is unable to do it naturally. Intermittent catheter consists of a drainage bag that assists to capture the urine. These catheters are
Continuous Glucose Monitoring Systems Market Registering A CAGR Of 22.9% By 2024
Continuous glucose monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM system is a type of glucose monitoring device that functions by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in interstitial fluid or blood, and transmits the information using a transmitter to a receiver/monitor for displaying the results. These systems play an integral role in

All 5 Releases


More Releases for CINV

CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the
Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Excellent Growth Scop …
A new research study from HTF MI with title Global Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs Market Size, Status and Forecast 2025 provides an in-depth assessment of the Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs investments till 2022. Access
Chemotherapy-induced Nausea and Vomiting (CINV) Treatment Market Analysis And Fo …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience
CINV Existing and Pipeline Drugs Market Projected to Reach US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
CINV Existing and Pipeline Drugs Market to Perceive Substantial Growth During 20 …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” the business intelligence firm says that
Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 …
Chemotherapy-induced Nausea and Vomiting (CINV) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022. Access Full Summary At: https://www.alliedmarketresearch.com/cinv-market Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with